4D Molecular Therapeutics FDMT Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $72.49M+20.3% | $60.24M+24.1% | $48.56M-37.1% | $77.16M-42.2% | $133.53M-10.6% | ||
| $318.4M-7.0% | $342.41M+33.5% | $256.51M+18.7% | $216.07M+15.0% | $187.91M-31.8% | ||
| $42.33M+8.6% | $38.98M+1.1% | $38.56M-3.9% | $40.11M-1.5% | $40.74M+3.7% | ||
| $405.36M-1.9% | $413.13M+32.3% | $312.38M+3.0% | $303.29M-8.8% | $332.57M-23.5% | ||
| $13.59M-8.6% | $14.87M-8.0% | $16.15M-7.7% | $17.51M-6.6% | $18.75M-4.0% | ||
| $17.36M-4.3% | $18.14M-4.0% | $18.91M-3.8% | $19.65M-3.5% | $20.37M-3.3% | ||
| $9.86M+7.3% | $9.19M-2.0% | $9.38M-0.1% | $9.39M+33.3% | $7.04M+65.3% | ||
| $512.91M-9.5% | $566.71M+33.7% | $423.98M-10.5% | $473.64M-8.2% | $515.73M-8.0% | ||
| $41.41M+34.1% | $30.87M+28.1% | $24.1M+19.5% | $20.16M+35.4% | $14.89M-0.4% | ||
| $22.87M-14.9% | $26.87M+11.1% | $24.19M+26.1% | $19.19M+18.4% | $16.2M-14.1% | ||
| $360K0.0% | $360K0.0% | $360K-66.2% | $1.07M+23.1% | $866K+237% | ||
| $5.49M-1.9% | $5.59M-1.8% | $5.7M-0.5% | $5.72M+0.7% | $5.68M+0.7% | ||
| $2.13M+185% | $745K-10.8% | $835K+281% | $219K-49.5% | $434K-58.9% | ||
| $43.4M-1.3% | $43.99M+18.5% | $37.11M+7.0% | $34.68M+28.9% | $26.9M-7.7% | ||
| $15.05M-4.9% | $15.82M-4.5% | $16.57M-4.5% | $17.36M-4.5% | $18.17M-4.2% | ||
| $20.54M-4.1% | $21.41M-3.8% | $22.26M-3.5% | $23.08M-3.3% | $23.85M-3.1% | ||
| $121K-12.3% | $138K-4.2% | $144K-10.6% | $161K-9.0% | $177K-8.3% | ||
| $61.07M0.0% | $61.05M+11.0% | $55M+4.3% | $52.75M+14.7% | $46.01M-7.6% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $5K-16.7% | $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $1.24B+1.3% | $1.22B+10.6% | $1.1B+0.4% | $1.1B+0.5% | $1.09B+0.6% | ||
| -$785.06M-9.6% | -$716.3M+2.6% | -$735.7M-8.4% | -$678.83M-8.8% | -$624.17M-8.3% | ||
| -$180K-125% | $727K+8.3% | $671K+99.1% | $337K+1.5% | $332K+45.0% | ||
| $451.84M-10.6% | $505.66M+37.0% | $368.98M-12.3% | $420.89M-10.4% | $469.72M-8.0% | ||
| $512.91M-9.5% | $566.71M+33.7% | $423.98M-10.5% | $473.64M-8.2% | $515.73M-8.0% | ||
| —— | —— | —— | —— | —— | ||
| $318.4M-7.0% | $342.41M+33.5% | $256.51M+18.7% | $216.07M+15.0% | $187.91M-31.8% | ||
| $9.86M+7.3% | $9.19M-2.0% | $9.38M-0.1% | $9.39M+33.3% | $7.04M+65.3% | ||
| $17.36M-4.3% | $18.14M-4.0% | $18.91M-3.8% | $19.65M-3.5% | $20.37M-3.3% | ||
| $17.36M-4.3% | $18.14M-4.0% | $18.91M-3.8% | $19.65M-3.5% | $20.37M-3.3% | ||
| $9.86M+7.3% | $9.19M-2.0% | $9.38M-0.1% | $9.39M+33.3% | $7.04M+65.3% | ||
| $17.36M-4.3% | $18.14M-4.0% | $18.91M-3.8% | $19.65M-3.5% | $20.37M-3.3% | ||
| $9.86M+7.3% | $9.19M-2.0% | $9.38M-0.1% | $9.39M+33.3% | $7.04M+65.3% | ||
| $2.13M+185% | $745K-10.8% | $835K+281% | $219K-49.5% | $434K-58.9% | ||
| $22.87M-14.9% | $26.87M+11.1% | $24.19M+26.1% | $19.19M+18.4% | $16.2M-14.1% | ||
| $22.87M-14.9% | $26.87M+11.1% | $24.19M+26.1% | $19.19M+18.4% | $16.2M-14.1% | ||
| $370K+3.4% | $358K+3.8% | $345K+3.3% | $334K+3.7% | $322K-21.5% | ||
| $2.13M+185% | $745K-10.8% | $835K+281% | $219K-49.5% | $434K-58.9% | ||
| $370K+3.4% | $358K+3.8% | $345K+3.3% | $334K+3.7% | $322K-21.5% | ||
| $2.13M+185% | $745K-10.8% | $835K+281% | $219K-49.5% | $434K-58.9% | ||
| $20.54M-4.1% | $21.41M-3.8% | $22.26M-3.5% | $23.08M-3.3% | $23.85M-3.1% | ||
| $1.24B+1.3% | $1.22B+10.6% | $1.1B+0.4% | $1.1B+0.5% | $1.09B+0.6% | ||
| $5K-16.7% | $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $370K+3.4% | $358K+3.8% | $345K+3.3% | $334K+3.7% | $322K-21.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are 4D Molecular Therapeutics's total assets?
- 4D Molecular Therapeutics (FDMT) holds $512.9M in total assets, down 0.5% year over year.
- How much debt does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics carries $20.5M in total debt against $451.8M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics holds $72.5M in cash and equivalents.
- Can 4D Molecular Therapeutics cover its short-term obligations?
- Its current ratio is 9.34 — current assets exceed current liabilities.
- Where does 4D Molecular Therapeutics's balance sheet data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
